ICON plc (ICLR)
Summary
Icon PLC (ICLR) Up 2.5% Since Last Earnings Report: Can It Continue?
Icon PLC (ICLR) reported earnings 30 days ago. What's next for the stock?
Is ICON a Buy as Valuation Improves but Earnings Risks Still Persist?
ICLR's discounted valuation and $23.4B backlog support upside potential, but falling estimates, weaker margins and execution risks argue for patience.
ICLR Jumps 33.2% in Three Months as Recovery Expectations Strengthen
ICON's 33.2% rally is backed by stronger proposal flow, bookings and backlog, but weaker earnings and margins cloud the recovery.
ICON plc Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 9,885 | $1.73M | $1.62M | -$113,578.75 | -6.57% |
| BZ Brandon Zatopek Commonwealth Equity Services LLC | 4,634 | $804,976 | $762,339.29 | -$42,636.71 | -5.3% |
| JC JoAnn Conry HUDSON EDGE INVESTMENT PARTNERS Inc. | 366,477 | $80.03M | $59.94M | -$20.09M | -25.1% |
| PN Peter Nicholson First Bancorp Inc. /ME/ | 124 | $21,540.04 | $20,590.2 | -$949.84 | -4.41% |
| SN Stephen Nickel CULLEN INVESTMENT GROUP Ltd. | 2,173 | $615,111.23 | $355,437.63 | -$259,673.6 | -42.22% |
ICON plc (ICLR) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has ICON plc ever had a stock split?
ICON plc Profile
| Professional Services Industry | Industrials Sector | Barry Balfe CEO | NASDAQ (NGS) Exchange | G4705A100 CUSIP |
| IE Country | 40,200 Employees | - Last Dividend | 13 Aug 2008 Last Split | 15 May 1998 IPO Date |
Overview
ICON Public Limited Company stands as a prominent clinical research organization (CRO) delivering comprehensive outsourced development and commercialization services across Ireland, rest of Europe, the United States, and globally. With its incorporation in 1990 and headquartering in Dublin, Ireland, ICON specializes in facilitating the strategic development, management, and analysis of programs spanning the entire clinical development spectrum from compound selection through to Phase I-IV clinical studies. Catering to the pharmaceutical, biotechnology, medical device industries, and government and public health organizations, ICON is dedicated to advancing medical research and bringing innovations to market more efficiently.
Products and Services
The array of services offered by ICON is versatile, covering every facet of clinical development and commercialization:
- Clinical Development Services: These encompass all stages of drug development, from early phase to peri and post-approval studies, offering comprehensive data solutions alongside site and patient access services. ICON's approach is designed to streamline the clinical trial process, ensuring efficiency and efficacy.
- Clinical Trial Management: ICON provides meticulous management of clinical trials, including consulting, contract staffing, and full study execution, tailored to meet the unique needs of each project and ensure its successful completion.
- Commercial Services: From clinical development strategy and trial design to full study execution and post-market commercialization, ICON offers a range of services aimed at maximizing the market potential of new medical products.
- Laboratory Services: The company’s laboratory services are broad-ranging, encompassing bionanalytical, biomarker, vaccine, good manufacturing practice (GMP), and central laboratory services. ICON delivers reliable and accurate test results, crucial for the success of clinical trials.
- Partnership Models: ICON offers both full-service and functional service partnerships, catering to the varied needs of its customers by providing tailored solutions that align with their strategic objectives.
- Specialized Solutions: This includes a plethora of services such as adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory services, commercial positioning, decentralized and hybrid clinical trials, early clinical development, laboratories, language services, medical imaging, real-world intelligence, and strategic solutions designed to address specific challenges within the clinical trial and pharmaceutical development processes.
